Indeed, along with the HER2+, there is HER2-low category (defined as IHC 1+ or IHC 2+ without HER2 gene amplification), comprehending approximately 50–55% of all primary BC [30,33▪]. This evidence concerns the gene ERBB2 and breast cancer.